Search hospitals > Washington > Renton

Rainier Clinical Research Center

Claim this profile
Renton, Washington 98057
Global Leader in Diabetes
Global Leader in Type 2 Diabetes
Conducts research for Type 1 Diabetes
Conducts research for Diabetic Neuropathy
Conducts research for Obesity
156 reported clinical trials
5 medical researchers
Photo of Rainier Clinical Research Center in RentonPhoto of Rainier Clinical Research Center in Renton

Summary

Rainier Clinical Research Center is a medical facility located in Renton, Washington. This center is recognized for care of Diabetes, Type 2 Diabetes, Type 1 Diabetes, Diabetic Neuropathy, Obesity and other specialties. Rainier Clinical Research Center is involved with conducting 156 clinical trials across 62 conditions. There are 5 research doctors associated with this hospital, such as Ronald Brazg, MD, Frances Eileen Broyles, Frances Broyles, MD, and Alissa Levinson, MD.

Top PIs

Clinical Trials running at Rainier Clinical Research Center

Obesity
Type 2 Diabetes
Diabetes
Diabetic Neuropathy
Type 1 Diabetes
Neuralgia
Osteoarthritis
Obstructive Sleep Apnea
Flu
Obesity/Overweight
Image of trial facility.

BI 456906

for Diabetes and Obesity

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.
Recruiting1 award Phase 37 criteria
Image of trial facility.

BI 456906

for Obesity

This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more and at least one health problem related to their weight. People with type 2 diabetes cannot take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.
Recruiting1 award Phase 37 criteria
Image of trial facility.

Retatrutide

for Obesity

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.
Recruiting1 award Phase 39 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Rainier Clinical Research Center?
Rainier Clinical Research Center is a medical facility located in Renton, Washington. This center is recognized for care of Diabetes, Type 2 Diabetes, Type 1 Diabetes, Diabetic Neuropathy, Obesity and other specialties. Rainier Clinical Research Center is involved with conducting 156 clinical trials across 62 conditions. There are 5 research doctors associated with this hospital, such as Ronald Brazg, MD, Frances Eileen Broyles, Frances Broyles, MD, and Alissa Levinson, MD.